



25 April 2007

Company Announcements Office
Australian Stock Exchange Limited
Level 4
20 Bridge Street
Sydney NSW 2000
Fax: +612 9778 0999

Select Vaccines Limited
Suite 15
545 St Kilda Road
Melbourne VIC 3004
Fax: +61 3 9529 2622

By facsimile - for immediate release

Replacement notice of initial substantial holding

In accordance with Chapter 6C of the Corporations Act 2001, AVANT encloses ASIC Form 603 (Notice of initial substantial holder) in relation to the fully paid ordinary shares in Select Vaccines Limited.

This form replaces the earlier Form 603, which was filed by AVANT with ASX on 24 April 2007.

Yours sincerely

A handwritten signature in black ink, appearing to read "Avery W. Catlin".

Avery W. Catlin
Senior Vice President, Chief
Financial Officer and Secretary

603 page 1/2 15 July 2001

Form 603Corporations Act 2001
Section 671B**Notice of initial substantial holder**To: Company Name/Scheme Select Vaccines Limited
ACN/ARSN 062 063 692**1. Details of substantial holder (1)**Name AVANT Immunotherapeutics Inc
ACN/ARSN (if applicable) N/A

The holder became a substantial holder on 19/04/07

2. Details of voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

Class of securities (4)	Number of securities	Person's votes (5)	Voting power (6)
Ordinary Shares	29,518,072	29,518,072	11.56%

3. Details of relevant interests

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities
AVANT Immunotherapeutics Inc	Direct holding under section 608(1)(a)	29,518,072 fully paid ordinary shares

4. Details of present registered holders

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
AVANT Immunotherapeutics Inc	AVANT Immunotherapeutics Inc	N/A	29,518,072 fully paid ordinary shares

5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant interest	Date of acquisition	Consideration (9)		Class and number of securities
		Cash	Non-cash	
AVANT Immunotherapeutics Inc	19/04/07	US\$735,000		29,518,072 fully paid ordinary shares

603 page 2/2 15 July 2001

6. Associates

The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
N/A	N/A

7. Addressee

The addresses of the persons named in this form are as follows:

Name	Address
AVANT Immunotherapeutics Inc	119 Fourth Avenue, Needham, Massachusetts 02464-2725, USA

Signature


print name

Avery W. Catlin

capacity

Secretary

sign here



date //

25 April 2007

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg, a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form.
- (2) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (3) See the definition of "relevant interest" in sections 606 and 671B(7) of the Corporations Act 2001.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an associate has a relevant interest in.
- (6) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
- (7) Include details of:
 - (a) any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of the relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (8) If the substantial holder is unable to determine the identity of the person (eg if the relevant interest arises because of an option) write "unknown".
- (9) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.